<p>In the pivotal ENGOT-OV16 study, adverse reactions (ADRs) occurring &gt; 10% of patients receiving Niraparib monotherapy were nausea, thrombocytopenia, fatigue/asthenia, anaemia, constipation, vomiting, abdominal pain, neutropenia, insomnia, headache, decreased appetite, nasopharyngitis, diarrhoea, dyspnea, hypertension, dyspepsia, back pain, dizziness, cough, urinary tract infection, arthralgia, palpitations, and dysgeusia. The most common serious adverse reactions &gt;1% (treatment-emergent frequencies) were thrombocytopenia and anaemia.</p>